(E)-ethyl 3-(5-bromopyridin-2-yl)acrylate | 876160-31-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (E)-ethyl 3-(5-bromopyridin-2-yl)acrylate
• 英文别名: ethyl (E)-3-(5-bromopyridin-2-yl)prop-2-enoate
• CAS: 876160-31-5
• 化学式: C₁₀H₁₀BrNO₂
• 分子量: 256.099
• InChiKey: BFPKQFHPRDXZPZ-AATRIKPKSA-N

物化性质

• 沸点：
  327.3±27.0 °C(Predicted)
• 密度：
  1.452±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-ethyl 3-(5-bromopyridin-2-yl)acrylate 在 sodium tetrahydroborate 、 copper(l) chloride 作用下， 以 甲醇 为溶剂， 反应 5.0h， 以60%的产率得到ethyl 3-(5-bromopyridin-2-yl)propanoate
  参考文献：
  名称：

  TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF

  摘要：

  提供了一种由化合物（I）或其药学上可接受的盐组成的药物，已被证明对治疗PRC2介导的疾病或紊乱有用：其中R1、R2、R3、R4、R5和n的定义如本文所述。

  公开号：

  US20160176882A1
• 作为产物：
  描述：

  5-溴-2-吡啶甲醛 、 溴乙酸乙酯 在 碳酸氢钠 、 三苯基膦 作用下， 以 水 、 乙酸乙酯 为溶剂， 反应 16.0h， 以85%的产率得到(E)-ethyl 3-(5-bromopyridin-2-yl)acrylate
  参考文献：
  名称：

  [EN] IMIDAZOPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER
  [FR] COMPOSÉS D'IMIDAZOPYRIMIDINE UTILES POUR LE TRAITEMENT DU CANCER

  摘要：

  提供了一种具有以下结构式（IA）的化合物，或其药用盐，已被证明对治疗PRC2介导的疾病或紊乱有用：其中A，R3，R4，R6和R7如本文所定义。

  公开号：

  WO2017221100A1

文献信息

• [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSÉS THÉRAPEUTIQUES
  申请人：UNIV WAYNE STATE

  公开号：WO2011079305A1

  公开（公告）日：2011-06-30

  The invention provides compounds of formula I or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for inducing apoptosis or treating cancer using compounds of formula I.

  该发明提供了如下所述的式I化合物或其盐。该发明还提供了包括式I化合物的药物组合物，制备式I化合物的方法，用于制备式I化合物的有用中间体以及利用式I化合物诱导凋亡或治疗癌症的治疗方法。
• SULFONAMIDE COMPOUNDS AND THE USE
  申请人：OGAWA Masami

  公开号：US20100022601A1

  公开（公告）日：2010-01-28

  The sulfoneamide compounds having the following Formula (1), which can be used as an effective component of a CaSR antagonizing agent useful for prophylaxis and/or treatment of bone disorders including osteoporosis and etc., are provided. The compounds have an excellent activity of promoting PTH secretion. In addition, the compounds are useful as an effective component of a medicament for the prophylaxis and/or treatment of bone disorders such as osteoporosis, bone fracture, hypoparathyroidism and the like.

  提供以下式(1)的磺酰胺化合物，可用作预防或治疗包括骨质疏松症等骨疾病的CaSR拮抗剂的有效成分。这些化合物具有促进PTH分泌的卓越活性。此外，这些化合物还用作预防或治疗骨质疏松症、骨折、低甲状旁腺功能等骨疾病药物的有效成分。
• ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER
  申请人：Liang Chungen

  公开号：US20100216806A1

  公开（公告）日：2010-08-26

  Compounds of formula are HDAC inhibitors. These compounds are useful for the treatment of diseases such as cancer in humans or animals.

  这些化合物的化学式是HDAC抑制剂。这些化合物对于治疗人类或动物的癌症等疾病是有用的。
• Heteroatom-Substituted Analogues of Orphan Nuclear Receptor Small Heterodimer Partner Ligand and Apoptosis Inducer (<i>E</i>)-4-[3-(1-Adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic Acid
  作者：Zebin Xia、Lulu Farhana、Ricardo G. Correa、Jayanta K. Das、David J. Castro、Jinghua Yu、Robert G. Oshima、John C. Reed、Joseph A. Fontana、Marcia I. Dawson

  DOI：10.1021/jm200051z

  日期：2011.6.9

  (E)-4[3'-(1-Adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces the cell cycle arrest and apoptosis of cancer cells. Because its pharmacologic properties solubility, bioavailability, and toxicity required improvement for translation, structural modifications were made by introducing nitrogen atoms into the cinnamyl ring and replacing its E-double bond with XCH2 (X = O, N, and S) with the objective of enhancing these properties without impacting apoptosis-inducing activity. Analogues having nitrogen atoms in heterocyclic rings corresponding to the cinnamyl phenyl ring displayed equal or higher biological activities. The pyrimidine and pyridine analogues were more soluble in both phosphate-buffered saline and water. While the 2,5-disubstituted pyridine analogue was the most potent inducer of KG-1 acute myeloid leukemia cell apoptosis, on the basis of apoptotic activity in KG-1 cells and solubility, the 2,5-disubstituted pyrimidine proved to be the more promising candidate for treatment of acute myeloid leukemia.

  (E)-4([3'-亚胺基-4'-羟基苯基])3-氯丙烯酸包围苯环诱导癌细胞周期阻滞和凋亡。为了改进其药理活性，如溶解度、生物利用度和毒性，引入了氮原子到苯环的羟基取代位点，并将双键改 became XCH2（X = O，N，S），以提高药理活性/毒性。具有含N原子的杂环对应于表间环部分的类药物显示了相等或更高的生物活性。而含有嘌呤的对位的二甲苯碱和二甲基并环二甲苯碱相当容易在磷酸缓冲盐和水这些易溶溶剂中暴漏。其中，二甲苯并二取代的苯碱类药物是最有效诱导粒流感-1（KG-1）急性髓系白血病细胞凋亡的药物。基于对粒流感-1细胞的凋亡作用和社会性，二苯基苯碱似乎在急性髓系白血病治疗方面是一个更为有前途的候选药物。
• [EN] HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC)<br/>[FR] COMPOSÉS D'HYDROXYAMIDE PRÉSENTANT UNE ACTIVITÉ EN TANT QU'INHIBITEURS D'HISTONE DÉSACÉTYLASE (HDAC)
  申请人：ASTELLAS PHARMA INC

  公开号：WO2006016680A1

  公开（公告）日：2006-02-16

  A compound having the following formula (I): wherein R1 is hydrogen, lower alkyl, lower alkenyl, lower or higher alkynyl, cyclo(lower)alkyl, cyclo(higher)alkyl, cyclo(lower)alkyl(lower)alkyl, cyclo(higher)alkyl(lower)alkyl, cyclo(lower)alkenyl(lower)alkyl, aryl-fused cyclo(lower)alkyl, lower alkoxy, acyl, aryl, ar(lower)alkoxy, ar(lower)alkyl, heteroar(lower)alkyl, amino, heteroaryl, heterocyclyl or heterocyclyl(lower)alkyl, which may be substituted with one or more suitable substituent(s),R2 is hydrogen or lower alkyl, X is arylene, heteroarylene, cycloalkylene, heterocycloalkylene or aryl-fused cycloalkylene, Y is arylene or heteroarylene, which may be substituted with one or more suitable substituent(s), Z is lower alkenylene, which may be substituted with lower alkyl or halogen, or a salt thereof. The compound is useful as a histone deacetylase inhibitor.

  一种具有以下化学式（I）的化合物：其中R1是氢、低烷基、低烯基、低或高炔基、环（低）烷基、环（高）烷基、环（低）烷基（低）烷基、环（高）烷基（低）烷基、环（低）烯基（低）烷基、芳基-融合环（低）烷基、低烷氧基、酰基、芳基、芳基（低）氧基、芳基（低）烷基、杂环芳基（低）烷基、氨基、杂环芳基、杂环烷基或杂环烷基（低）烷基，可以用一个或多个适当的取代基替换；R2是氢或低烷基，X是芳基、杂环芳基、环烷基、杂环环烷基或芳基-融合环烷基，Y是芳基或杂环芳基，可以用一个或多个适当的取代基替换；Z是低烯基，可以用低烷基或卤素取代，或其盐。该化合物可用作组蛋白去乙酰化酶抑制剂。